Further in‐depth analysis is needed to reveal whether FGF‐2 is indeed directly involved in the growth and differentiation of ET HSPCs, which may suggest a new avenue for targeted interventions in MPN. This evidence concerns the gene FGF2 and myeloproliferative disorder.